GPCR News and Research

RSS

Insilico Medicine releases frontier AI models for drug discovery

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the release of a series of frontier specialist models for chemistry and biology, trained through its MMAI Gym for Science framework.

2 Sep 2026

New EV-SELEX strategy accelerates drug discovery for wide range of GPCRs

G protein-coupled receptors (GPCRs) are the most abundantly expressed proteins in the human body, which regulate diverse physiological processes ranging from pain perception to hormone signaling.

7 Jul 2026

Duke researchers discover molecules that target vital cell signaling proteins

To function normally, nearly every cell in the human body relies on G-protein coupled receptors (GPCRs) to receive and send signals. That's why GPCRs are targeted by roughly one-third of all FDA‑approved drugs.

24 Jun 2026

Scientists identify unique receptor that accelerates early neuron growth

Cells have surface receptors that couple to proteins and other molecules to initiate or inhibit certain behaviors.

17 Jun 2026

Study suggests new potentially druggable ways to target GPCR signaling

A study published in Nature by researchers at Duke University School of Medicine identifies a new way that G protein–coupled receptors (GPCRs) - targets of roughly one-third of FDA-approved drugs - control signaling in cells.

27 May 2026

AI-created miniproteins show promise for targeting hard-to-treat diseases

G protein-coupled receptors, or GPCRs, sit in the plasma membrane, the boundary that defines the inside and outside of a living cell. They communicate with nearly every physiological process in our bodies - from the ability to see and smell, to sensing of adrenaline, insulin, nutrients and medicines.

21 May 2026

NIH awards $3.9 million grant to develop a non-opioid pain treatment

The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH), has awarded a $3.9 million grant to a multi-institutional team led by scientists at Sanford Burnham Prebys Medical Discovery Institute to develop a non-opioid pain therapeutic and advance it into a Phase 1 clinical trial.

4 May 2026

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026

Nuclera launches GPCR-focused nanodisc panel to streamline membrane protein production

Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs).

From Nuclera 30 Mar 2026

Parasites trigger a gut-to-brain signal that cuts food intake during infection

Researchers found that intestinal tuft cells signal to crypt enterochromaffin cells by releasing acetylcholine, triggering serotonin release and activating a gut-to-brain vagal pathway during type 2 inflammation. This sustained signalling, rather than the initial acute response, was linked to reduced food intake in mouse models of parasitic infection.

29 Mar 2026

Thermodynamic insights into histamine H1 receptor ligand binding

G-protein-coupled receptors (GPCRs) are one of the largest families of cell surface proteins in the human body that recognize hormones, neurotransmitters, and drugs.

13 Feb 2026

New signaling molecule drives development of tissue resident memory T cells

We owe a lot to tissue resident memory T cells (TRM). These specialized immune cells are among the body's first responders to disease.

22 Nov 2025

Urolithin A recharges aging immune cells and boosts mitochondrial fitness in midlife adults

Urolithin A, a natural postbiotic known to trigger mitophagy, rejuvenated key immune cell functions in healthy middle-aged adults after 28 days. The trial showed a shift toward a youthful, energy-efficient CD8⁺ T-cell profile and enhanced bacterial clearance without inflammatory side effects.

3 Nov 2025

Molecular bumpers and glues rewire GPCR signaling for next-generation medicines

New research led by the University of Minnesota Medical School demonstrates that molecules acting as "molecular bumpers" and "molecular glues" can rewire G protein-coupled receptor (GPCR) signaling, turning the cell's busiest receptors into precision tools - opening the door to a new generation of safer, smarter medicines.

31 Oct 2025

A single drug stabilizes nearly all mutations of key kidney protein

A study published today in Nature Structural & Molecular Biology is the first time researchers have shown evidence that a single drug, already licensed for medical use, can stabilize nearly all mutated versions of a human protein, regardless of where the mutation is in the sequence.

23 Sep 2025

Targeting amino acid networks could lead to more precise medicines

Amino acids play a fundamental role in regulating how cells respond to drugs. These molecules, which form proteins, act like bricks that communicate with each other within a structure.

16 Jul 2025

Advancing GPCR drug discovery with fragment screening using GCI technology

Evotec's insights into GPCRs and waveRAPID technology reveal new opportunities in drug discovery, focusing on orphan receptors and innovative screening methods.

From Creoptix (A Malvern Panalytical brand) 23 May 2025

Scientists unlock secrets of how cells navigate the body

Scientists from St. Jude Children's Research Hospital and the Medical College of Wisconsin have created a data science framework to better understand how cells travel through the body.

23 Apr 2025

Gut bacteria may reduce the effectiveness of common medications

A new study, published today in Nature Chemistry by researchers from the University of Pittsburgh and Yale University, shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective.

3 Apr 2025

Groundbreaking study reveals new pathways to modulate cell behavior

Cell membrane proteins hide secret gateways that can be used to modify cell behavior. This has been demonstrated in a study led by the Hospital del Mar Research Institute and published in Nature Communications, with participation from research centers in Spain, Switzerland, the United Kingdom, Germany, France, Poland, the Netherlands, Denmark, Hungary, Italy, Sweden, China, and the United States.

27 Mar 2025